Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2004

View Archived Issues

Recordati to market Cidine in Spain

Cephalon reaches agreement in principle with FTC on CIMA merger

ID Biomedical's acquisition of Shire's vaccine business nears completion

Treatment completed in phase III trial of Neurodex for PBA in MS patients

CF-101 enters phase I study in solid tumor patients

Point Therapeutics commences last planned phase II studies for talabostat

Kyowa Hakko returns to Geron Asian rights to telomerase inhibitors

Six series of urotensin II antagonists and their use reported by GSK

Merck researchers identify novel GABA-A receptor ligands for anxiety and other disorders

Merck claims new beta-secretase inhibitors and their use in AD therapy

Novel DPP-IV inhibitors in early development at Merck

GSK scientists present novel LXR agonists in a recent patent

Novel antiangiogenic agents targeting Tie-2, VEGFR and/or Raf kinases

Solvay submits NDA for cilansetron

TargeGen selects TG-100435 for clinical development in oncology and edema

Prevacid approved for use in adolescents

Enrollment commences in trial of Xyrem for fibromyalgia

Combigyrase consortium receives funding for development of novel antibiotics

Proof-of-concept for fipamezole in Parkinson's patients

KuDOS retains access to innovative research into DNA repair

European study of Progenta for uterine fibroids

Orathecin MAA submitted in Europe

Ilex shareholders approve merger with Genzyme

Uriach and Organon collaborate on kinase inhibitors for inflammatory diseases

sNDA for Atacand in chronic heart failure

Mixed MAO-A and MAO-B inhibitor promising for Parkinson's disease therapy

Antidiabetic effects of novel nonthiazolidinedione insulin sensitizer FK-614

Potent, selective and orally active cannabinoid antagonist promising for modulation of appetite

Recent news on statin therapy

Update on testosterone for male hypogonadism and HSDD